Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity

Gentzon Hall, Janelle Rowell, Federica Farinelli, Rasheed A. Gbadegesin, Peter Lavin, Guanghong Wu, Alison Homstad, Andrew Malone, Thomas Lindsey, Ruiji Jiang, Robert Spurney, Gordon F. Tomaselli, David A Kass, Michelle P. Winn

Research output: Contribution to journalArticle

Abstract

The emerging role of the transient receptor potential cation channel isotype 6 (TRPC6) as a central contributor to various pathological processes affecting podocytes has generated interest in the development of therapeutics to modulate its function. Recent insights into the regulation of TRPC6 have revealed PKG as a potent negative modulator of TRPC6 conductance and associated signaling via its phosphorylation at two highly conserved amino acid residues: Thr69/Thr70 (Thr69 in mice and Thr70 in humans) and Ser321/Ser322 (Ser321 in mice and Ser322 in humans). Here, we tested the role of PKG in modulating TRPC6-dependent responses in primary and conditionally immortalized mouse podocytes. TRPC6 was phosphorylated at Thr69 in nonstimulated podocytes, but this declined upon ANG II stimulation or overexpression of constitutively active calcineurin phosphatase. ANG II induced podocyte motility in an in vitro wound assay, and this was reduced 30-60% in cells overexpressing a phosphomimetic mutant TRPC6 (TRPC6T70E/S322E) or activated PKG (P <0.05). Pretreatment of podocytes with the PKG agonists S-nitroso-N-acetyl-DL-penicillamine (nitric oxide donor), 8-bromo-cGMP, Bay 41-2772 (soluble guanylate cyclase activator), or phosphodiesterase 5 (PDE5) inhibitor 4-{[3′,4′-(methylenedioxy)benzyl]amino}[7]-6-methoxyquinazoline attenuated ANG II-induced Thr69 dephosphorylation and also inhibited TRPC6-dependent podocyte motility by 30-60%. These data reveal that PKG activation strategies, including PDE5 inhibition, ameliorate ANG II-induced podocyte dysmotility by targeting TRPC6 in podocytes, highlighting the potential therapeutic utility of these approaches to treat hyperactive TRPC6-dependent glomerular disease.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Renal Physiology
Volume306
Issue number12
DOIs
StatePublished - Jun 15 2014

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
Transient Receptor Potential Channels
Cyclic GMP-Dependent Protein Kinases
Podocytes
Down-Regulation
Phosphodiesterase 5 Inhibitors
Penicillamine
Nitric Oxide Donors
Pathologic Processes
Phosphorylation
Amino Acids

Keywords

  • Calcineurin
  • Phosphodiesterase 5
  • Podocyte
  • Protein kinase G
  • Transient receptor potential cation channel isotype 6

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. / Hall, Gentzon; Rowell, Janelle; Farinelli, Federica; Gbadegesin, Rasheed A.; Lavin, Peter; Wu, Guanghong; Homstad, Alison; Malone, Andrew; Lindsey, Thomas; Jiang, Ruiji; Spurney, Robert; Tomaselli, Gordon F.; Kass, David A; Winn, Michelle P.

In: American Journal of Physiology - Renal Physiology, Vol. 306, No. 12, 15.06.2014.

Research output: Contribution to journalArticle

Hall, G, Rowell, J, Farinelli, F, Gbadegesin, RA, Lavin, P, Wu, G, Homstad, A, Malone, A, Lindsey, T, Jiang, R, Spurney, R, Tomaselli, GF, Kass, DA & Winn, MP 2014, 'Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity', American Journal of Physiology - Renal Physiology, vol. 306, no. 12. https://doi.org/10.1152/ajprenal.00212.2013
Hall, Gentzon ; Rowell, Janelle ; Farinelli, Federica ; Gbadegesin, Rasheed A. ; Lavin, Peter ; Wu, Guanghong ; Homstad, Alison ; Malone, Andrew ; Lindsey, Thomas ; Jiang, Ruiji ; Spurney, Robert ; Tomaselli, Gordon F. ; Kass, David A ; Winn, Michelle P. / Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. In: American Journal of Physiology - Renal Physiology. 2014 ; Vol. 306, No. 12.
@article{b5928c87a9ce46c18f3e12c43524e8b3,
title = "Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity",
abstract = "The emerging role of the transient receptor potential cation channel isotype 6 (TRPC6) as a central contributor to various pathological processes affecting podocytes has generated interest in the development of therapeutics to modulate its function. Recent insights into the regulation of TRPC6 have revealed PKG as a potent negative modulator of TRPC6 conductance and associated signaling via its phosphorylation at two highly conserved amino acid residues: Thr69/Thr70 (Thr69 in mice and Thr70 in humans) and Ser321/Ser322 (Ser321 in mice and Ser322 in humans). Here, we tested the role of PKG in modulating TRPC6-dependent responses in primary and conditionally immortalized mouse podocytes. TRPC6 was phosphorylated at Thr69 in nonstimulated podocytes, but this declined upon ANG II stimulation or overexpression of constitutively active calcineurin phosphatase. ANG II induced podocyte motility in an in vitro wound assay, and this was reduced 30-60{\%} in cells overexpressing a phosphomimetic mutant TRPC6 (TRPC6T70E/S322E) or activated PKG (P <0.05). Pretreatment of podocytes with the PKG agonists S-nitroso-N-acetyl-DL-penicillamine (nitric oxide donor), 8-bromo-cGMP, Bay 41-2772 (soluble guanylate cyclase activator), or phosphodiesterase 5 (PDE5) inhibitor 4-{[3′,4′-(methylenedioxy)benzyl]amino}[7]-6-methoxyquinazoline attenuated ANG II-induced Thr69 dephosphorylation and also inhibited TRPC6-dependent podocyte motility by 30-60{\%}. These data reveal that PKG activation strategies, including PDE5 inhibition, ameliorate ANG II-induced podocyte dysmotility by targeting TRPC6 in podocytes, highlighting the potential therapeutic utility of these approaches to treat hyperactive TRPC6-dependent glomerular disease.",
keywords = "Calcineurin, Phosphodiesterase 5, Podocyte, Protein kinase G, Transient receptor potential cation channel isotype 6",
author = "Gentzon Hall and Janelle Rowell and Federica Farinelli and Gbadegesin, {Rasheed A.} and Peter Lavin and Guanghong Wu and Alison Homstad and Andrew Malone and Thomas Lindsey and Ruiji Jiang and Robert Spurney and Tomaselli, {Gordon F.} and Kass, {David A} and Winn, {Michelle P.}",
year = "2014",
month = "6",
day = "15",
doi = "10.1152/ajprenal.00212.2013",
language = "English (US)",
volume = "306",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "12",

}

TY - JOUR

T1 - Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity

AU - Hall, Gentzon

AU - Rowell, Janelle

AU - Farinelli, Federica

AU - Gbadegesin, Rasheed A.

AU - Lavin, Peter

AU - Wu, Guanghong

AU - Homstad, Alison

AU - Malone, Andrew

AU - Lindsey, Thomas

AU - Jiang, Ruiji

AU - Spurney, Robert

AU - Tomaselli, Gordon F.

AU - Kass, David A

AU - Winn, Michelle P.

PY - 2014/6/15

Y1 - 2014/6/15

N2 - The emerging role of the transient receptor potential cation channel isotype 6 (TRPC6) as a central contributor to various pathological processes affecting podocytes has generated interest in the development of therapeutics to modulate its function. Recent insights into the regulation of TRPC6 have revealed PKG as a potent negative modulator of TRPC6 conductance and associated signaling via its phosphorylation at two highly conserved amino acid residues: Thr69/Thr70 (Thr69 in mice and Thr70 in humans) and Ser321/Ser322 (Ser321 in mice and Ser322 in humans). Here, we tested the role of PKG in modulating TRPC6-dependent responses in primary and conditionally immortalized mouse podocytes. TRPC6 was phosphorylated at Thr69 in nonstimulated podocytes, but this declined upon ANG II stimulation or overexpression of constitutively active calcineurin phosphatase. ANG II induced podocyte motility in an in vitro wound assay, and this was reduced 30-60% in cells overexpressing a phosphomimetic mutant TRPC6 (TRPC6T70E/S322E) or activated PKG (P <0.05). Pretreatment of podocytes with the PKG agonists S-nitroso-N-acetyl-DL-penicillamine (nitric oxide donor), 8-bromo-cGMP, Bay 41-2772 (soluble guanylate cyclase activator), or phosphodiesterase 5 (PDE5) inhibitor 4-{[3′,4′-(methylenedioxy)benzyl]amino}[7]-6-methoxyquinazoline attenuated ANG II-induced Thr69 dephosphorylation and also inhibited TRPC6-dependent podocyte motility by 30-60%. These data reveal that PKG activation strategies, including PDE5 inhibition, ameliorate ANG II-induced podocyte dysmotility by targeting TRPC6 in podocytes, highlighting the potential therapeutic utility of these approaches to treat hyperactive TRPC6-dependent glomerular disease.

AB - The emerging role of the transient receptor potential cation channel isotype 6 (TRPC6) as a central contributor to various pathological processes affecting podocytes has generated interest in the development of therapeutics to modulate its function. Recent insights into the regulation of TRPC6 have revealed PKG as a potent negative modulator of TRPC6 conductance and associated signaling via its phosphorylation at two highly conserved amino acid residues: Thr69/Thr70 (Thr69 in mice and Thr70 in humans) and Ser321/Ser322 (Ser321 in mice and Ser322 in humans). Here, we tested the role of PKG in modulating TRPC6-dependent responses in primary and conditionally immortalized mouse podocytes. TRPC6 was phosphorylated at Thr69 in nonstimulated podocytes, but this declined upon ANG II stimulation or overexpression of constitutively active calcineurin phosphatase. ANG II induced podocyte motility in an in vitro wound assay, and this was reduced 30-60% in cells overexpressing a phosphomimetic mutant TRPC6 (TRPC6T70E/S322E) or activated PKG (P <0.05). Pretreatment of podocytes with the PKG agonists S-nitroso-N-acetyl-DL-penicillamine (nitric oxide donor), 8-bromo-cGMP, Bay 41-2772 (soluble guanylate cyclase activator), or phosphodiesterase 5 (PDE5) inhibitor 4-{[3′,4′-(methylenedioxy)benzyl]amino}[7]-6-methoxyquinazoline attenuated ANG II-induced Thr69 dephosphorylation and also inhibited TRPC6-dependent podocyte motility by 30-60%. These data reveal that PKG activation strategies, including PDE5 inhibition, ameliorate ANG II-induced podocyte dysmotility by targeting TRPC6 in podocytes, highlighting the potential therapeutic utility of these approaches to treat hyperactive TRPC6-dependent glomerular disease.

KW - Calcineurin

KW - Phosphodiesterase 5

KW - Podocyte

KW - Protein kinase G

KW - Transient receptor potential cation channel isotype 6

UR - http://www.scopus.com/inward/record.url?scp=84902683099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902683099&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00212.2013

DO - 10.1152/ajprenal.00212.2013

M3 - Article

C2 - 24740790

AN - SCOPUS:84902683099

VL - 306

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 12

ER -